Results 41 to 50 of about 789,217 (259)

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

Elucidating the molecular basis of a novel autosomal dominant fibrotic syndrome [PDF]

, 2009
Includes abstract.Includes bibliographical references (leaves 97-103).A novel fibrotic syndrome was recently reported in a South African family, characterised by poikiloderma, tendon contracture and progressive pulmonary fibrosis.
Watson, Lauren
core   +1 more source

Validation of gene editing efficiency with CRISPR-Cas9 system directly in rat zygotes using electroporation mediated delivery and embryo culture

MethodsX, 2021
Successful use of the CRISPR-Cas9 system for gene manipulation relies on identifying effective and efficient guide RNA sequences (gRNAs). When the goal is to create transgenic animal/rodent models by knocking-in desired sequences using homology-directed ...
Anil K. Challa, Denise Stanford, Antonio Allen, Lawrence Rasmussen, Ferdinand K. Amanor, S. Vamsee Raju   +5 more
doaj   +1 more source

Interstitial pulmonary fibrosis

Chest, 1986
The study of animal models of IPF has demonstrated that there is a stereotyped response of the respiratory airspace walls to a wide variety of injuries. Inflammatory and immune effector cells play a major and complex role in the fibrosing process. They may contribute to the injury of the lung beyond the original insult.
openaire   +2 more sources

Quality of life is associated with physical activity and fitness in cystic fibrosis [PDF]

, 2014
BACKGROUND: Health-related and disease-specific quality of life (HRQoL) has been increasingly valued as relevant clinical parameter in cystic fibrosis (CF) clinical care and clinical trials.
Helge Hebestreit, Schmid, K, Junge, Sibylle, Hebestreit, Helge Uwe, Hebestreit, H, Schindler, C, Schmid, Kerstin, Kriemler, Susi, Christian Schindler, Schenk, T, Hebestreit, Alexandra, Ballmann, Manfred, Hebestreit, A, Kerstin Schmid, Stephanie Kieser, Hans-Georg Posselt, Manfred Ballmann, Thomas Schenk, Roth, K, Schenk, Thomas, Junge, S, Posselt, H G, Posselt, Hans-Georg, Sibylle Junge, Alexandra Hebestreit, Kieser, Stephanie, Hebestreit, Helge, Ballmann, M, Susi Kriemler, Schindler, Christian, Roth, Kristina, Kristina Roth   +31 more
core   +2 more sources

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Downregulation of HMGCS2 mediated AECIIs lipid metabolic alteration promotes pulmonary fibrosis by activating fibroblasts

Respiratory Research
Background Abnormal lipid metabolism has recently been reported as a crucial signature of idiopathic pulmonary fibrosis (IPF). However, the origin and biological function of the lipid and possible mechanisms of increased lipid content in the pathogenesis
Juntang Yang, Xin Pan, Min Xu, Yingge Li, Chenxi Liang, Lulu Liu, Zhongzheng Li, Lan Wang, Guoying Yu   +8 more
doaj   +1 more source

Effects of Systemic Enzyme Supplements on Symptoms and Quality of Life in Patients with Pulmonary Fibrosis—A Pilot Study

Medicines, 2021
Current FDA-approved antifibrotic treatments for Idiopathic Pulmonary Fibrosis slow down disease progression but have little impact on symptoms or quality of life in patients.
Neha Shah
doaj   +1 more source

Hydrogel platforms for 3D cardiac tissue engineering and fibrotic disease modelling

FEBS Open Bio, EarlyView.
Hydrogel‐based cardiac tissue models are advancing our understanding of heart health and disease. By incorporating electrical conductivity, aligned structures, and tunable mechanical properties, these platforms better replicate the complex environment of native heart tissue.
Harrison Porritt, Annika Winbo, Jenny Malmström   +2 more
wiley   +1 more source

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design [PDF]

, 2019
INTRODUCTION: Forced vital capacity is the only registrational endpoint in idiopathic pulmonary fibrosis clinical trials. As most new treatments will be administered on top of standard of care, estimating treatment response will become more challenging ...
Meyvisch, Paul, Santermans, Eva, Wijsenbeek, Marlies, Ford, Paul, Wuyts, Wim A, Maher, Toby M, Kreuter, M, Meyvisch, P, Molyneaux, Philip L., Wijsenbeek - Lourens, Marlies, Verbruggen, Nadia, Molyneaux, Philip L, Brown, Kevin K, Lederer, DJ, Maher, Toby M., Brown, KK, Molyneaux, PL, Byrne, AJ, Wuyts, WA, Lederer, David J, Moor, Catharina C, Brown, Kevin K., Moor, Karen, Byrne, Adam J, Lederer, David J., Maher, TM, Byrne, Adam J., Sivananthan, A, Sivananthan, Arunon, Kreuter, Michael, Ford, P, Verbruggen, N, Santermans, E, Moor, Catharina C., Wuyts, Wim A., Verbruggen, N. (Nadia), Moor, C.C. (Karen), Lederer, D.J. (David J.), Wuyts, W.A. (Wim A.), Ford, P. (Paul), Santermans, E. (Eva), Brown, K.K. (Kevin K.), Byrne, A.J. (Adam J.), Wijsenbeek-Lourens, M.S. (Marlies), Molyneaux, P.L. (Philip L.), Kreuter, M. (Michael), Maher, T.M. (Toby M.), Meyvisch, P. (Paul), Sivananthan, A. (Arunon)   +48 more
core   +1 more source